We investigated the effect of BCL2 inhibition by Venetoclax alone or combined with Nilotinib [19] in cells derived from chronic phase CML (CP-CML) and Ph+ ALL patients expressing p210 and p190 BCR-ABL1 isoforms, respectively. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.